HIV/AIDS Research

Pharma company makes three antiretroviral formulation filings to WHO

Published in Vaccine Weekly, June 29th, 2005

Ranbaxy Laboratories Limited (Ranbaxy) announced that the company has made three filings of its antiretroviral (ARVs) formulations, to the World Health Organization (WHO) for its approval under the latter's prequalification project for HIV/AIDS drugs.

This takes the total number of filings submitted by Ranbaxy to the WHO to eleven, of which, five are fixed dose combinations (FDCs). All the ARVs filed by the company to WHO are manufactured at a plant inspected and approved by the U.S. Food and Drug Administration (FDA). The contract research organizations used by Ranbaxy to carry out these bioequivalence studies are globally reputed and conduct and file their studies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry